JP2019068852A5 - - Google Patents

Download PDF

Info

Publication number
JP2019068852A5
JP2019068852A5 JP2019006734A JP2019006734A JP2019068852A5 JP 2019068852 A5 JP2019068852 A5 JP 2019068852A5 JP 2019006734 A JP2019006734 A JP 2019006734A JP 2019006734 A JP2019006734 A JP 2019006734A JP 2019068852 A5 JP2019068852 A5 JP 2019068852A5
Authority
JP
Japan
Prior art keywords
vector
polypeptide
vaccine composition
protein
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019006734A
Other languages
English (en)
Japanese (ja)
Other versions
JP6748240B2 (ja
JP2019068852A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019068852A publication Critical patent/JP2019068852A/ja
Publication of JP2019068852A5 publication Critical patent/JP2019068852A5/ja
Application granted granted Critical
Publication of JP6748240B2 publication Critical patent/JP6748240B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019006734A 2015-08-20 2019-01-18 治療用ｈｐｖ１８ワクチン Expired - Fee Related JP6748240B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15181791.3 2015-08-20
EP15181791 2015-08-20
EP16156334 2016-02-18
EP16156334.1 2016-02-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018509566A Division JP6470872B2 (ja) 2015-08-20 2016-08-18 治療用ｈｐｖ１８ワクチン

Publications (3)

Publication Number Publication Date
JP2019068852A JP2019068852A (ja) 2019-05-09
JP2019068852A5 true JP2019068852A5 (https=) 2019-10-03
JP6748240B2 JP6748240B2 (ja) 2020-08-26

Family

ID=56787465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018509566A Expired - Fee Related JP6470872B2 (ja) 2015-08-20 2016-08-18 治療用ｈｐｖ１８ワクチン
JP2019006734A Expired - Fee Related JP6748240B2 (ja) 2015-08-20 2019-01-18 治療用ｈｐｖ１８ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018509566A Expired - Fee Related JP6470872B2 (ja) 2015-08-20 2016-08-18 治療用ｈｐｖ１８ワクチン

Country Status (21)

Country Link
US (3) US9790256B2 (https=)
EP (1) EP3337500A1 (https=)
JP (2) JP6470872B2 (https=)
KR (1) KR20180042295A (https=)
CN (1) CN107921110B (https=)
AU (2) AU2016309743B2 (https=)
BR (1) BR112018003019A2 (https=)
CA (1) CA2995740A1 (https=)
CL (1) CL2018000432A1 (https=)
CO (1) CO2018001623A2 (https=)
EA (1) EA037295B1 (https=)
HK (1) HK1252967A1 (https=)
IL (1) IL257604A (https=)
JO (1) JO3765B1 (https=)
MX (1) MX2018002106A (https=)
MY (1) MY195389A (https=)
SA (1) SA518390954B1 (https=)
SG (1) SG10202001501QA (https=)
TW (1) TWI744246B (https=)
WO (1) WO2017029360A1 (https=)
ZA (2) ZA201801119B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
JP7053491B2 (ja) * 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
MX2020003071A (es) 2017-09-23 2020-07-28 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresion de paramyxoviridae.
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
EP3810277A1 (en) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US20230405105A1 (en) 2019-09-20 2023-12-21 Transgene Sa Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20210353744A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines Prevention B.V. Administration of homologous adenoviral vectors
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12275766B2 (en) 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
JP2024539188A (ja) * 2021-10-22 2024-10-28 イノビオ ファーマシューティカルズ，インコーポレイティド 肛門高悪性度扁平上皮内病変（ｈｓｉｌ）を治療するための組成物及び方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
KR101271884B1 (ko) 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
CN103122360A (zh) 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CN101100672B (zh) * 2007-06-06 2010-05-26 曾毅 经修饰的hpv e6-e7融合基因及其编码蛋白
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
CN101591646B (zh) * 2008-05-27 2012-05-30 清华大学深圳研究生院 一种治疗人宫颈癌的树突状细胞疫苗
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
BR112014015016B1 (pt) * 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN103864936B (zh) * 2012-12-11 2018-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン

Similar Documents

Publication Publication Date Title
JP2019068852A5 (https=)
JP2018148890A5 (https=)
US8337859B2 (en) Vectors for multiple gene expression
EP2118292B1 (en) Papillomavirus e2 polypeptide used for vaccination
RU2008145712A (ru) Вакцина против папилломовирусной инфекции на основе вируса папиломы человека впч-16
JP2010516287A5 (https=)
JP2020519614A5 (https=)
US20100055069A1 (en) Hpv-18-based papillomavirus vaccines
CN107080833A (zh) 作为广谱人类乳头状瘤病毒（hpv）疫苗的乳头状瘤病毒样颗粒（vlp）
JP2019514943A5 (https=)
CN101952320B (zh) 具有免疫原性的物质
RU2005109155A (ru) Днк-вакцина, кодирующая по меньшей мере два неструктурных ранних белка вируса папилломы
CN119736337A (zh) Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗
JP2002532434A5 (https=)
JP2006516386A5 (https=)
CN102649963A (zh) 可用于食管癌防治的基于hpv l1基因的重组腺病毒
AbouZaid Oncogenic viruses and cancer: a review of literature on their global burden
US6926897B1 (en) Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU3521499A (en) Medicament for preventing or treating papilloma virus-specific tumors
Guo et al. Development Status and trend of HPV vaccine
HK1135731B (en) Vectors for multiple gene expression
AU2013201033A1 (en) Papillomavirus E2 Polypeptide Used for Vaccination